WVP
BCDA icon

Worth Venture Partners’s BioCardia BCDA Stock Holding History

Worth Venture Partners’s Portfolio BCDA Stock Details BCDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,373
Closed -$246K – 172
2023
Q1 		$246K Sell
8,373
-1,389
-14% -$46.1K 0.12% 116
2022
Q4 		$306K Buy
+9,762
New +$278K 0.18% 95

Other funds holding BCDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
FM
Family Management New York $834M AUM 20.83% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Worth Venture Partners's BCDA Position: Q2 2023 in Review

Worth Venture Partners sold out of BioCardia (BCDA) in Q2 2023, closing a stake of 8,373 shares — an estimated $246K sold.

Worth Venture Partners first reported a position in BCDA in Q4 2022 and held it in 2 quarters. The position peaked at $306K in Q4 2022. 23 funds tracked by Wall St. Rank hold BCDA as of Q2 2023.

  • Worth Venture Partners reported no remaining BioCardia position as of Q2 2023 after selling out during the quarter.
  • Worth Venture Partners sold 8,373 BioCardia shares in Q2 2023, an estimated $246K.
  • Worth Venture Partners first reported a position in BioCardia in Q4 2022 and held it in 2 quarters.
  • Worth Venture Partners's BioCardia position peaked at $306K in Q4 2022.
  • 23 funds tracked by Wall St. Rank held BioCardia as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.